Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Balance Sheet

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4.23	3.15	17.09	40.18	36.78
Short-Term Investments	291.9	219.09	211.45	-	-
Cash & Short-Term Investments	296.12	222.24	228.54	40.18	36.78
Cash Growth	33.24%	-2.76%	468.79%	9.23%	52.07%
Accounts Receivable	19.37	172.91	12.8	-	0.01
Other Receivables	7.17	2.42	1.61	1.09	1.42
Receivables	26.54	175.33	14.41	1.09	1.42
Prepaid Expenses	9.57	0.4	4.21	1.98	1.84
Other Current Assets	-	1.36	-	-	-
Total Current Assets	332.23	399.33	247.16	43.25	40.04
Property, Plant & Equipment	0.05	0.03	0.04	0.02	0.01
Long-Term Deferred Tax Assets	10.58	10.35	0.77	-	-
Total Assets	342.86	409.71	247.97	43.27	40.06
Accounts Payable	0.88	1.45	0.68	0.26	0.25
Accrued Expenses	1.53	1.45	2.74	0.72	0.56
Current Income Taxes Payable	-	42.87	37.12	-	-
Other Current Liabilities	1.94	-	2.23	0.7	-
Total Current Liabilities	4.34	45.76	42.76	1.68	0.8
Pension & Post-Retirement Benefits	0.07	0.04	-	-	-
Total Liabilities	4.41	45.8	42.76	1.68	0.8
Common Stock	134.94	165.27	173.13	167.74	167.58
Retained Earnings	210.87	180.43	38.39	-118.69	-118.88
Comprehensive Income & Other	-7.36	18.2	-6.31	-7.46	-9.45
Shareholders' Equity	338.45	363.9	205.21	41.59	39.25
Total Liabilities & Equity	342.86	409.71	247.97	43.27	40.06
Net Cash (Debt)	296.12	222.24	228.54	40.18	36.78
Net Cash Growth	33.24%	-2.76%	468.79%	9.23%	52.07%
Net Cash Per Share	2.26	1.70	1.75	0.31	0.31
Filing Date Shares Outstanding	126.64	127.01	127.27	125.97	125.97
Total Common Shares Outstanding	126.64	127.01	127.27	125.97	125.97
Working Capital	327.9	353.57	204.39	41.57	39.24
Book Value Per Share	2.67	2.87	1.61	0.33	0.31
Tangible Book Value	338.45	363.9	205.21	41.59	39.25
Tangible Book Value Per Share	2.67	2.87	1.61	0.33	0.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.